Learn More
Choroideremia (CHM) is an X- linked retinal degeneration that is symptomatic in the 1(st) or 2(nd) decade of life causing nyctalopia and loss of peripheral vision. The disease progresses through mid-life, when most patients become blind. CHM is a favorable target for gene augmentation therapy, as the disease is due to loss of function of a protein necessary(More)
In " AAV-mediated gene therapy for Choroideremia: Preclinical studies in personalized in vitro models " , by Vasireddy et al (DOI: 10.1371/journal.pone.0061396), two panels in Fig 1 contained immunoblot images that were spliced together by the authors for the sake of reordering lanes and omitting unnecessary data on the published figure. The authors(More)
  • 1